BridgeBio Gets First Drug Approval In Ultra-Rare MoCD Type A
Executive Summary
Although small patient base offers modest revenue opportunity, the Nulibry approval enables BridgeBio to get commercial operations underway.
You may also be interested in...
Apollo’s Next Steps: Apply Learnings From Prior Hub-And-Spoke Entities
Apollo’s $145m financing will help advance its 15-plus candidate portfolio into clinical development. With Patient Square leading the round, its expertise with BridgeBio and co. will help guide Apollo’s evolution.
BridgeBio’s Hub-And-Spoke Model: An Interview With Cameron Turtle
Since raising $135m in 2017 to address rare, monogenic diseases, BridgeBio has launched or purchased 17 companies and built a pipeline of 30-plus candidates. Scrip checked in as the company nears commercialization.
The Next Roivant Or Fortress? BridgeBio Raises $135m To Spin Out New Companies
BridgeBio's hub-and-spoke model is similar to the Roivant and Fortress strategies, but with a focus on drug candidates for genetic diseases in need of a bridge to future funding.